title: Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C.
abstract: OBJECTIVE
  Hepatic stellate cells only produce fibronectin isoforms in disease states. The isoform-defining domains can be detected in the blood circulation. This study examines whether circulating levels of fibronectin isoforms show a relationship with liver fibrosis on histology in patients with chronic hepatitis C.
  
  
  METHODS
  In a prospective study, 50 patients with chronic hepatitis C who underwent a liver biopsy were compared to 50 matched controls and 35 patients with other liver conditions.
  
  
  RESULTS
  Circulating levels of the fibronectin isoforms were significantly higher in patients with chronic hepatitis C compared to healthy controls [oncofetal fibronectin (oFN) 2.45 +/- 0.17 versus 1.76 +/- 0.16 mg/l, P < 0.005; extra domain-A (EDA) 1.05 +/- 0.06 versus 0.86 +/- 0.06 mg/l, P < 0.05; and extra domain-B (EDB) 14.55 +/- 0.74 versus 9.31 +/- 0.58 mg/l, P < 0.001], even though total fibronectin was lower (198.9 +/- 3.5 versus 343.6 +/- 14.5 mg/l, P < 0.001). A correlation with the fibrosis score was found for both oFN (r = 0.46, P < 0.005) and EDA (r = 0.51, P < 0.001). The combination of an elevation in both markers (oFN and EDA) in the upper quartile was associated with a specificity of > 99% for predicting significant fibrosis (stages 2-4) and 95% for predicting advanced fibrosis (stages 3-4). A combination of decreased values in the lowest tertile for both markers had a specificity of 94% for excluding significant fibrosis. Based on these findings, 30% of the patients scheduled for a liver biopsy could be correctly classified as having or not having significant fibrosis. The remainder would have to proceed with a biopsy.
  
  
  CONCLUSIONS
  Circulating fibronectin isoforms produced by activated stellate cells represent a viable marker for the presence of significant fibrosis or a lack thereof.
authors.affiliation: Max-Planck Institute for Biochemistry, Martinsried, Germany.
authors.forename: Norman J
authors.initials: NJ
authors.lastname: Hackl
authors.forename: Claus
authors.initials: C
authors.lastname: Bersch
authors.forename: Peter
authors.initials: P
authors.lastname: Feick
authors.forename: Christoph
authors.initials: C
authors.lastname: Antoni
authors.forename: Andreas
authors.initials: A
authors.lastname: Franke
authors.forename: Manfred V
authors.initials: MV
authors.lastname: Singer
authors.forename: Inaam A
authors.initials: IA
authors.lastname: Nakchbandi
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D001707:Biopsy, Needle; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D005260:Female; D005353:Fibronectins / Q000097:blood*; D055166:Hepatic Stellate Cells / Q000378:metabolism; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000473:pathology; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood* / Q000209:etiology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D020033:Protein Isoforms / Q000097:blood*
chemical_list: D015415:Biomarkers; D005353:Fibronectins; D020033:Protein Isoforms